⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetone SCHEMBL222610 | 0.82 | — | — | |
| Acetone SCHEMBL1603144 | 0.82 | — | — | |
| Acetone SCHEMBL18875610 | 0.82 | — | — | |
| Acetone SCHEMBL11252464 | 0.82 | — | — | |
| Acetone SCHEMBL626214 | 0.75 | — | — | |
| Acetone SCHEMBL304055 | 0.73 | — | — | |
| Acetone SCHEMBL8091689 | 0.72 | — | — | |
| Acetone SCHEMBL19281749 | 0.67 | — | — | |
| Acetone SCHEMBL3859411 | 0.66 | — | — | |
| Acetic Acid SCHEMBL9987037 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576156-B2 | Compound comprising self-immolative group and ligand-drug conjugate comprising same | TRIOAR, INC. (KR) | 2026-03-17 | — | — | US | disclosed |
| US-12384789-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4545096-A1 | COMPOUND COMPRISING SELF-IMMOLATIVE GROUP AND LIGAND-DRUG CONJUGATE COMPRISING SAME | Trioar, Inc. (KR) | 2025-04-30 | — | — | EP | disclosed |
| US-20250121072-A1 | COMPOUND COMPRISING SELF-IMMOLATIVE GROUP AND LIGAND-DRUG CONJUGATE COMPRISING SAME | TRIOAR, INC. (KR) | 2025-04-17 | — | — | US | disclosed |
| CN-119451701-A | Compounds comprising self-destructing groups and ligand-drug conjugates comprising the same | 特里奥尔株式会社 | 2025-02-14 | — | — | CN | disclosed |
| CN-111065626-B | Compounds for the treatment of huntington's disease | PTC医疗公司 | 2024-09-27 | — | — | CN | disclosed |
| WO-2024194467-A2 | CATALYTIC DECARBOXYLATION REACTIONS USING IONIC LIQUIDS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-09-26 | — | — | WO | disclosed |
| EP-4434995-A1 | CATALYTIC DECARBOXYLATION REACTIONS USING IONIC LIQUIDS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-09-25 | — | — | EP | disclosed |
| EP-4387610-A1 | TRICYCLIC SULTAMS AND SULFAMIDES AS ANTITUMOR AGENTS | Peloton Therapeutics, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024118524-A1 | AZAINDOLE COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | CEREVEL THERAPEUTICS, LLC (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2023040996-A1 | AZAINDAZOLE MACROCYCLIC COMPOUND AND USE THEREOF | 北京伯汇生物技术有限公司 | 2023-03-23 | — | — | WO | disclosed |
| EP-4151627-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20230080054-A1 | INHIBITORS OF ANOCTAMIN 6 PROTEIN AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-03-16 | — | — | US | disclosed |
| US-20220251098-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2022-08-11 | — | — | US | disclosed |
| US-11407753-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| EP-3116509-B1 | A NEW CLASS OF MU-OPIOID RECEPTOR AGONISTS | UNIV COLUMBIA (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20220162193-A1 | PYRAZOLESULFONAMIDES AS ANTITUMOR AGENTS | PELOTON THERAPEUTICS, INC. (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220106279-A1 | CLASS OF MU-OPIOID RECEPTOR AGONISTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-04-07 | — | — | US | disclosed |
| EP-2603509-A1 | CRYSTALLINE FORM OF PYRIMIDIO[6,1-A]ISOQUINOLIN-4-ONE COMPOUND | Verona Pharma PLC (GB) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012020016-A1 | CRYSTALLINE FORM OF PYRIMIDIO[6,1-A]ISOQUINOLIN-4-ONE COMPOUND | VERONA PHARMA PLC (GB) | 2012-02-16 | — | — | WO | disclosed |